{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:16:48Z","timestamp":1791965808177,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005927","name":"Daiichi Sankyo Foundation of Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41588-025-02468-9","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:03:02Z","timestamp":1769076182000},"page":"355-365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genomic evolution of pancreatic cancer at single-cell resolution"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-9491","authenticated-orcid":false,"given":"Haochen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palash","family":"Sashittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0823-1519","authenticated-orcid":false,"given":"Elias-Ramzey","family":"Karnoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Jakatdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-1515","authenticated-orcid":false,"given":"Shigeaki","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungeui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Agustin","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7149-4572","authenticated-orcid":false,"given":"Amanda","family":"Erakky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin A.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7424-8127","authenticated-orcid":false,"given":"Akimasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hilmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-959X","authenticated-orcid":false,"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-048X","authenticated-orcid":false,"given":"Benjamin J.","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-3023","authenticated-orcid":false,"given":"Christine A.","family":"Iacobuzio-Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2468_CR1","unstructured":"American Cancer Society. Survival rates for pancreatic cancer. www.cancer.org\/cancer\/types\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html (2025)."},{"key":"2468_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib, L., Wehner, M. R., Matrisian, L. M. & Nead, K. T. Estimated projection of US cancer incidence and death to 2040. JAMA Netw. Open 4, e214708 (2021).","journal-title":"JAMA Netw. Open"},{"key":"2468_CR3","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-12-1215","volume":"18","author":"S Yachida","year":"2012","unstructured":"Yachida, S. et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin. Cancer. Res. 18, 6339\u20136347 (2012).","journal-title":"Clin. Cancer. Res."},{"key":"2468_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378\u2013382 (2016).","journal-title":"Nature"},{"key":"2468_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41586-022-05082-5","volume":"608","author":"T Baslan","year":"2022","unstructured":"Baslan, T. et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature 608, 795\u2013802 (2022).","journal-title":"Nature"},{"key":"2468_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer. Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer. Res."},{"key":"2468_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ccell.2018.12.010","volume":"35","author":"AA Connor","year":"2019","unstructured":"Connor, A. A. et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell 35, 267\u2013282 (2019).","journal-title":"Cancer Cell"},{"key":"2468_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231\u2013240 (2020).","journal-title":"Nat. Genet."},{"key":"2468_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2468_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3, 272\u2013286 (2022).","journal-title":"Nat. Cancer"},{"key":"2468_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"2468_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"2468_CR13","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2135\u20132161 (2024).","journal-title":"Cancer Discov."},{"key":"2468_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36344-z","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer. Nat. Commun. 14, 749 (2023).","journal-title":"Nat. Commun."},{"key":"2468_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","volume":"18","author":"A Hayashi","year":"2021","unstructured":"Hayashi, A., Hong, J. & Iacobuzio-Donahue, C. A. The pancreatic cancer genome revisited. Nat. Rev. Gastroenterol. Hepatol. 18, 469\u2013481 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2468_CR16","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1073\/pnas.0601273103","volume":"103","author":"N Bardeesy","year":"2006","unstructured":"Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl Acad. Sci. USA 103, 5947\u20135952 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2468_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-23-1541","volume":"15","author":"KM Mullen","year":"2025","unstructured":"Mullen, K. M. et al. The evolutionary forest of pancreatic cancer. Cancer Discov. 15, 329\u2013345 (2025).","journal-title":"Cancer Discov."},{"key":"2468_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41586-025-08980-6","volume":"642","author":"M Gozdecka","year":"2025","unstructured":"Gozdecka, M. et al. Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis. Nature 642, 431\u2013441 (2025).","journal-title":"Nature"},{"key":"2468_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03106-5","volume":"24","author":"P Sashittal","year":"2023","unstructured":"Sashittal, P., Zhang, H., Iacobuzio-Donahue, C. A. & Raphael, B. J. ConDoR: tumor phylogeny inference with a copy-number constrained mutation loss model. Genome Biol. 24, 272 (2023).","journal-title":"Genome Biol."},{"key":"2468_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ng.3764","volume":"49","author":"AP Makohon-Moore","year":"2017","unstructured":"Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49, 358\u2013366 (2017).","journal-title":"Nat. Genet."},{"key":"2468_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aat7171","volume":"361","author":"JG Reiter","year":"2018","unstructured":"Reiter, J. G. et al. Minimal functional driver gene heterogeneity among untreated metastases. Science 361, 1033\u20131037 (2018).","journal-title":"Science"},{"key":"2468_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature21356","volume":"543","author":"KM Turner","year":"2017","unstructured":"Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122\u2013125 (2017).","journal-title":"Nature"},{"key":"2468_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41568-025-00814-x","volume":"25","author":"K Naxerova","year":"2025","unstructured":"Naxerova, K. Evolutionary paths towards metastasis. Nat. Rev. Cancer 25, 545\u2013560 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2468_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-024-07359-3","volume":"629","author":"AM Braxton","year":"2024","unstructured":"Braxton, A. M. et al. 3D genomic mapping reveals multifocality of human pancreatic precancers. Nature 629, 679\u2013687 (2024).","journal-title":"Nature"},{"key":"2468_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"2468_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med. 31, 466\u2013477 (2025).","journal-title":"Nat. Med."},{"key":"2468_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00942-5","volume":"8","author":"MD Muzumdar","year":"2017","unstructured":"Muzumdar, M. D. et al. Survival of pancreatic cancer cells lacking KRAS function. Nat. Commun. 8, 1090 (2017).","journal-title":"Nat. Commun."},{"key":"2468_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","journal-title":"Cell"},{"key":"2468_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-018-0481-8","volume":"561","author":"AP Makohon-Moore","year":"2018","unstructured":"Makohon-Moore, A. P. et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561, 201\u2013205 (2018).","journal-title":"Nature"},{"key":"2468_CR30","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1101\/gad.1475506","volume":"20","author":"H Ijichi","year":"2006","unstructured":"Ijichi, H. et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-\u03b2 signaling in cooperation with active Kras expression. Genes Dev. 20, 3147\u20133160 (2006).","journal-title":"Genes Dev."},{"key":"2468_CR31","doi-asserted-by":"publisher","unstructured":"Yeh, C. et al. Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2566 (2025).","DOI":"10.1158\/1078-0432.CCR-25-2566"},{"key":"2468_CR32","doi-asserted-by":"publisher","first-page":"TPS4230","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4230","volume":"43","author":"BM Wolpin","year":"2025","unstructured":"Wolpin, B. M. et al. Trial in progress: RASolute 302\u2014a phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). J. Clin. Oncol. 43, TPS4230\u2013TPS4230 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2468_CR33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","volume":"10","author":"SJ Pettitt","year":"2020","unstructured":"Pettitt, S. J. et al. Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10, 1475\u20131488 (2020).","journal-title":"Cancer Discov."},{"key":"2468_CR34","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler, H. L. et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J. Clin. Oncol. 40, 3929\u20133939 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2468_CR35","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello, D., Elez, E., Tabernero, J. & Seoane, J. Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives. Ann. Oncol. 31, 1336\u20131349 (2020).","journal-title":"Ann. Oncol."},{"key":"2468_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccell.2020.03.008","volume":"37","author":"B Lim","year":"2020","unstructured":"Lim, B., Lin, Y. & Navin, N. Advancing cancer research and medicine with single-cell genomics. Cancer Cell 37, 456\u2013470 (2020).","journal-title":"Cancer Cell"},{"key":"2468_CR37","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1016\/j.cell.2023.07.024","volume":"186","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186, 3968\u20133982 (2023).","journal-title":"Cell"},{"key":"2468_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-022-05249-0","volume":"612","author":"T Funnell","year":"2022","unstructured":"Funnell, T. et al. Single-cell genomic variation induced by mutational processes in cancer. Nature 612, 106\u2013115 (2022).","journal-title":"Nature"},{"key":"2468_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"2468_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43018-019-0010-1","volume":"1","author":"A Hayashi","year":"2020","unstructured":"Hayashi, A. et al. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat. Cancer 1, 59\u201374 (2020).","journal-title":"Nat. Cancer"},{"key":"2468_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","journal-title":"Nat. Med."},{"key":"2468_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"2468_CR43","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).","journal-title":"Sci. Signal"},{"key":"2468_CR44","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I De Bruijn","year":"2023","unstructured":"De Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. 83, 3861\u20133867 (2023).","journal-title":"Cancer Res."},{"key":"2468_CR45","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2468_CR46","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","volume":"54","author":"WL Hwang","year":"2022","unstructured":"Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178\u20131191 (2022).","journal-title":"Nat. Genet."},{"key":"2468_CR47","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239\u20132254 (2021).","journal-title":"Cell"},{"key":"2468_CR48","doi-asserted-by":"publisher","unstructured":"Zhang, H. et al. Dataset for Zhang et al., \u2018genomic evolution of pancreatic cancer at single-cell resolution\u2019. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17155593 (2025).","DOI":"10.5281\/zenodo.17155593"},{"key":"2468_CR49","doi-asserted-by":"publisher","unstructured":"Zhang, H. haochenz96\/TapVarCallSmk: Zhang et al. Nature Genetics 2025. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17309019 (2025).","DOI":"10.5281\/zenodo.17309019"},{"key":"2468_CR50","doi-asserted-by":"publisher","unstructured":"Zhang, H., Sashittal, P. & Jakatdar, A. haochenz96\/tap_cn_calling: Zhang et al. Nature Genetics 2025. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17309013 (2025).","DOI":"10.5281\/zenodo.17309013"},{"key":"2468_CR51","doi-asserted-by":"publisher","unstructured":"Zhang, H. & Jakatdar, A. Bolladeen\/full-ConDoR: version 1.0.0\u2014initial public release. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17309066 (2025).","DOI":"10.5281\/zenodo.17309066"},{"key":"2468_CR52","doi-asserted-by":"publisher","unstructured":"Zhang, H. & Sashittal, P. haochenz96\/Tapestri_main_manuscript_analysis: Zhang et al. Nature Genetics 2025. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17309023 (2025).","DOI":"10.5281\/zenodo.17309023"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02468-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:04:27Z","timestamp":1770908667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1038\/s41588-025-02468-9","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.Z. owns equity in Revolution Medicines and engages in compensated professional activities with Valar Labs. M.H. receives research funding from Servier and Astellas, and receives honoraria from Pierre Fabre, Astrazeneca, Amgen and Viatris. W.P. receives research funding from the NIH\/NCI, Merck, Astellas, Lepu Biopharma, Amgen, Revolution Medicines, Break Through Cancer, Parker Institute for Cancer Immunotherapy, Society for Immunotherapy of Cancer and The Society of MSK; is a consulting and advisory board member of Astellas, EXACT Therapeutics, Revolution Medicines, Innovent Biologics and Regeneron Pharmaceuticals, KeyQuest and TD Cowen; and received honoraria for Continuing Medical Education\u2014American Physician Institute, Curio, Integrity and PER. E.M.O. receives institutional research funding from Genentech\/Roche, BioNTech, AstraZeneca, Arcus, Elicio Therapeutics, Parker Institute, the NIH\/NCI, Digestive Care, Break Through Cancer, Agenus, Amgen and Revolution Medicines; consults (uncompensated) for Arcus, Amgen, AstraZeneca, Ability Pharma, Alligator BioSciences, Pfizer, Agenus, BioNTech, Ipsen, Ikena, Merck, Immuneering, Moma Therapeutics, Novartis, Astellas, Bristol Myers Squibb, Revolution Medicines, Regeneron and Tango Therapeutics; and receives travel reimbursement from BioNTech and Arcus. A.C.W. receives consulting fees from Histosonics for Data and Safety Monitoring Board membership and receives institutional clinical trial funding from Ipsen. All roles are outside of the scope of this manuscript. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}